DermiAgeRandomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
HA matrix ingredient
+ Placebo
Otro tipo de estudio
Resumen
Fecha de inicio: 1 de octubre de 2022
Fecha en la que se inscribió al primer participante.This study includes 60 healthy volunteers in which will be evaluated if the oral supplement with Dermial \[composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%)\] is able to obtain differences versus placebo in healthy women showing natural signs of age-related aging versus placebo . It is a single-center, double-blind, randomized, placebo-controlled clinical study with proportion 1:1 between treatments.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 60 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Otro Tipo de Estudio
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.De 35 a 65 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Criterios
Inclusion Criteria: 1. Healthy women between 35 and 65 years of age (inclusive), showing signs of physiological facial skin aging. 2. Women willing not to use any firming product, skin lightening, or any other topical or systemic medication known to affect skin aging or dyschromia during the study period. 3. Be informed of the nature of the study and give their IC in writing. 4. Women willing not to become pregnant during the course of the study, using contraceptive methods considered highly effective. Exclusion Criteria: 1. Women with allergies to the ingredients in the investigational product. 2. Women who have used a dietary or nutricosmetic supplement containing HA, or who have undergone Botox or HA infiltrations, in the last 6 months prior to signing the IC. 3. Women who have undergone: * Superficial or medium-deep chemical peels or dermabrasion within the 6 weeks prior to signing the IC or inclusion document. * Deep facial chemical peel, non-ablative laser or fractional laser resurfacing in the 12 months prior to signing the IC or inclusion document. * Facial plastic surgery or a laser ablative procedure for photoaging in the 12 months prior to signing the IC or inclusion document. 4. Suspected uncontrolled disease, such as diabetes mellitus (DM), arterial hypertension (HT), hyperthyroidism or hypothyroidism, renal failure or liver failure. 5. Women who have received a PRP (Platelet Rich Plasma) injection as a treatment for aesthetic purposes, in the 3 months prior to inclusion by signing the IC. 6. Women who do not wish, for whatever reason, to take the supplements in the study. 7. Known pregnancy or lactation. 8. Presence of inflammatory skin disease such as psoriasis, atopic dermatitis, rosacea, acne or hidradenitis suppurativa. 9. Presence of active malignant pathologies or premalignant skin lesions such as actinic keratoses. 10. Psychiatric disorder that is not managed or any other circumstance or pathology that prevents the participant from understanding and/or complying with the study procedures.
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.2 grupos de intervención están designados en este estudio
50% de probabilidad de ser asignado al grupo placebo
Grupos de Tratamiento
Grupo I
ExperimentalGrupo II
PlaceboObjetivos del Estudio
Objetivos Primarios
Objetivos Secundarios
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene una ubicación